Precision oncology company Guardant Health announced on Monday that FDA has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic.

Roche subsidiary Foundation Medicine announced on Thursday that it is partnering with Boehringer Ingelheim to develop a companion diagnostic for the pharmaceutical firm's biliary tract cancer drug.

Foundation Medicine said Wednesday its FoundationOne Liquid CDx test has received approval from the US Food and Drug Administration as a companion diagnostic for Genentech's Rozlytrek (entrectinib).

Amoy (300685.SZ) and Beigene (NASDAQ: BGNE, HKEX: 06160, SSE: 688235) have recently entered into a strategic collaboration on companion diagnostics.

Amoy Diagnostics and Amgen on Thursday said that they have entered a strategic partnership to develop a companion diagnostic for the Japanese market to identify non-small cell lung cancer patients for Amgen's KRAS G12C inhibitor, sotorasib (Lumakras).

On August 5, 2021, Pillar Biosciences announced the FDA has given PMA to its oncoReveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors

Qiagen and OncXerna Therapeutics said on Monday that they have signed a master agreement to develop a next-generation sequencing companion diagnostic for navicixizumab, which OncXerna is developing as a treatment for patients with ovarian cancer.